GT Biopharma is trading 5.79% up at $6.30 on October 9, 2026, with no confirmed company-specific catalyst; broader biotech strength may be supporting shares. - XBI is up 2.50%, providing sector context, though its role in this move is unconfirmed. - The company’s press-release page lists its latest release as September 15, about a potential new indication for GTB-5550.